Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
Pfizer
Novartis
Tomsk National Research Medical Center of the Russian Academy of Sciences
Kivu Bioscience Inc.
Eli Lilly and Company
AstraZeneca
BeOne Medicines
ViroMissile, Inc.
EMD Serono
Replimune Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
Angiex, Inc.
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Iambic Therapeutics, Inc
General Oncology, Inc.
SystImmune Inc.
SN BioScience
Barbara Ann Karmanos Cancer Institute
Orano Med LLC
M.D. Anderson Cancer Center
Eli Lilly and Company
University of Washington
Pfizer
Jacobio Pharmaceuticals Co., Ltd.
MOMA Therapeutics
GlaxoSmithKline
Fate Therapeutics
NextCure, Inc.
Shanghai Juncell Therapeutics
Abramson Cancer Center at Penn Medicine
AstraZeneca
SystImmune Inc.
Actym Therapeutics, Inc.
EtiraRx Australia Pty Ltd
Sanofi
Exelixis
Indiana University
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Senhwa Biosciences, Inc.